Pulmatrix (NASDAQ:PULM) Shares Pass Above 50 Day Moving Average – Time to Sell?

Pulmatrix, Inc. (NASDAQ:PULM)’s stock price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.58 and traded as high as $1.72. Pulmatrix shares last traded at $1.66, with a volume of 17,326 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Pulmatrix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Pulmatrix Stock Up 1.5%

The stock has a market cap of $6.11 million, a P/E ratio of -1.36 and a beta of 1.91. The firm has a 50 day moving average price of $1.59 and a 200 day moving average price of $1.80.

Pulmatrix (NASDAQ:PULM) last released its earnings results on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. DRW Securities LLC acquired a new position in Pulmatrix, Inc. (NASDAQ:PULM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. 11.84% of the stock is owned by institutional investors.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).